pharmaceutical investing FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
pharmaceutical investing Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
pharmaceutical investing Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
pharmaceutical investing U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
pharmaceutical investing Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
pharmaceutical investing Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
pharmaceutical investing Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
pharmaceutical investing Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
pharmaceutical investing Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
pharmaceutical investing European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
pharmaceutical investing Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
pharmaceutical investing Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU
Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders
Nuvau Winter Drilling at Thundermine Returns 5.28 g/t Au over 6.1 m, Including 7.22 g/t Au over 3.1 m
